Weekly Investment Analysts’ Ratings Updates for Tango Therapeutics (TNGX)

Several brokerages have updated their recommendations and price targets on shares of Tango Therapeutics (NASDAQ: TNGX) in the last few weeks:

• 5/15/2026 – Tango Therapeutics had its price target raised by Mizuho from $20.00 to $30.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – Tango Therapeutics was downgraded by Piper Sandler from “overweight” to “neutral”. They now have a $24.00 price target on the stock, up from $16.00.
• 5/14/2026 – Tango Therapeutics was given a new $55.00 price target by UBS Group AG.
• 5/14/2026 – Tango Therapeutics was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $27.00 price target on the stock, up from $18.00.
• 5/14/2026 – Tango Therapeutics had its price target raised by Leerink Partners from $28.00 to $55.00. They now have an “outperform” rating on the stock.
• 5/14/2026 – Tango Therapeutics had its price target raised by Wedbush from $19.00 to $33.00. They now have an “outperform” rating on the stock.
• 5/11/2026 – Tango Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 4/27/2026 – Tango Therapeutics had its “buy” rating reaffirmed by Citigroup Inc..
• 4/27/2026 – Tango Therapeutics had its price target raised by Stifel Nicolaus from $24.00 to $40.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Tango Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 4/2/2026 – Tango Therapeutics is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $30.00 price target on the stock.
• 3/27/2026 – Tango Therapeutics had its “buy” rating reaffirmed by B. Riley Financial, Inc..

Insider Buying and Selling at Tango Therapeutics

In other news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $21.23, for a total value of $573,210.00. Following the sale, the insider directly owned 115,743 shares in the company, valued at approximately $2,457,223.89. This trade represents a 18.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have sold 179,056 shares of company stock valued at $3,346,181. 6.50% of the stock is currently owned by company insiders.

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.